68Ga-Labeled [Thz14]Bombesin(7-14) Analogs: Promising GRPR-Targeting Agonist PET Tracers with Low Pancreas Uptake

With overexpression in various cancers, the gastrin-releasing peptide receptor (GRPR) is a promising target for cancer imaging and therapy. However, the high pancreas uptake of reported GRPR-targeting radioligands limits their clinical application. Our goal was to develop Ga-68-labeled agonist tracers for detecting GRPR-expressing tumors with positron emission tomography (PET), and compare them with the clinically validated agonist PET tracer, [Ga-68]Ga-AMBA. Ga-TacBOMB2, TacBOMB3, and TacBOMB4, derived from [Thz(14)]Bombesin(7-14), were confirmed to be GRPR agonists by a calcium mobilization study, and their binding affinities (K-i(GRPR)) were determined to be 7.62 +/- 0.19, 6.02 +/- 0.59, and 590 +/- 36.5 nM, respectively, via in vitro competition binding assays. [Ga-68]Ga-TacBOMB2, [Ga-68]Ga-TacBOMB3, and [Ga-68]Ga-AMBA clearly visualized PC-3 tumor xenografts in a PET imaging study. [Ga-68]Ga-TacBOMB2 showed comparable tumor uptake but superior tumor-to-background contrast ratios when compared to [Ga-68]Ga-AMBA. Moreover, [Ga-68]Ga-TacBOMB2 and [Ga-68]Ga-TacBOMB3 showed a much lower rate of uptake in the pancreas (1.30 +/- 0.14 and 2.41 +/- 0.72%ID/g, respectively) than [Ga-68]Ga-AMBA (62.4 +/- 4.26%ID/g). In conclusion, replacing Met(14) in the GRPR-targeting sequence with Thz(14) retains high GRPR-binding affinity and agonist properties. With good tumor uptake and tumor-to-background uptake ratios, [Ga-68]Ga-TacBOMB2 is promising for detecting GRPR-expressing tumors. The much lower pancreas uptake of [Ga-68]Ga-TacBOMB2 and [Ga-68]Ga-TacBOMB3 suggests that [Thz(14)]Bombesin(7-14) is a promising targeting vector for the design of GRPR-targeting radiopharmaceuticals, especially for radioligand therapy application.

Automated summary

With overexpression in various cancers, the gastrin-releasing peptide receptor (GRPR) is a promising target for cancer imaging and therapy. Three Ga-68-labeled agonist tracers, Ga-TacBOMB2, TacBOMB3, and TacBOMB4, were developed and compared with the clinically validated agonist PET tracer, [Ga-68]Ga-AMBA. The results showed that [Ga-68]Ga-TacBOMB2 had comparable tumor uptake but superior tumor-to-background contrast ratios compared to [Ga-68]Ga-AMBA, and both [Ga-68]Ga-TacBOMB2 and [Ga-68]Ga-TacBOMB3 had much lower pancreas uptake than [Ga-68]Ga-AMBA. This suggests that [Thz(14)]Bombesin(7-14) is a promising targeting vector for GRPR-targeting radiopharmaceuticals.